Theralink® Technologies Announces Partnership with Perthera to Facilitate and Accelerate Access to its Unique Phosphoprotein and Drug Target Activation Testing in the U.S.
The alliance will facilitate and accelerate access to Theralink's 32 phosphoprotein panel, the Theralink assay, across the U.S. for breast cancer patients.
- The alliance will facilitate and accelerate access to Theralink's 32 phosphoprotein panel, the Theralink assay, across the U.S. for breast cancer patients.
- This unique assay is the world's only phosphoprotein panel LDT that directly measures the activation state of targets of over 100 precision therapeutics at once.
- Through this partnership, Perthera will develop and manage Theralink's observational registry trial, TRACE (Theralink Registry to Assess Comprehensive Effectiveness).
- We look forward to advancing our integrated partnership and driving Theralink's innovative testing across the nation," said Gary Gregory, CEO of Perthera.